Journal: Journal of Nanobiotechnology

Article Title: Manganese-loaded carbon nanoparticles ameliorate ANCA-associated vasculitis by inhibiting ferroptosis

doi: 10.1186/s12951-025-03725-z

Figure Lengend Snippet: Ferroptosis is present during ANCA-GN progression. ( A ) Expression of serum ferritin in healthy individuals ( n = 12) and ANCA-GN patients ( n = 28); ( B ) Expression of serum MDA in healthy individuals ( n = 12) and ANCA-GN patients ( n = 28); ( C ) Serum MnSOD activity in healthy individuals ( n = 12) and ANCA-GN patients ( n = 28); ( D ) Correlation analysis between serum cf-DNA and MDA in ANCA-GN patients ( n = 28); ( E ) Correlation analysis between serum MnSOD activity and MDA in ANCA-GN patients ( n = 28); ( F ) Expression of TFR1 in renal tissues of ANCA-GN patients and MPO-AAV rats, with glomeruli indicated by dashed lines, scale bar = 20 μm; ( G ) Western Blot analysis of changes in ferroptosis-related protein expression in MPO-AAV rats ( n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 AAV: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; ANCA-GN: ANCA-associated glomerulonephritis; MPO: Myeloperoxidase; HC: Health control; EAV: Experimental autoimmune vasculitis; HAS: Human serum albumin

Article Snippet: Western blotting (WB) was performed using specific primary antibodies against TFR1, manganese superoxide dismutase (MnSOD) (ABclonal, China), COX2 (Wanlei, China), CPX4 (Abcam), ICAM-1 (Proteintech, China), VCAM-1 (Boster, China) and GAPDH (Abways, China.

Techniques: Expressing, Activity Assay, Western Blot, Control

Journal: Nature Communications

Article Title: AAK1 activation-mediated iron trafficking drives ferroptotic cell death

doi: 10.1038/s41467-025-67523-9

Figure Lengend Snippet: A Protein levels associated with iron metabolism in various cancer cell lines treated with erastin for 12 h. A549, 8 μM; CAL51, 30 μM; HN6, 30 μM; HT1080, 4 μM; MDA-MB-231, 8 μM; MCF7, 30 μM. B , C Total ( B ) and divalent ( C ) iron levels of various cancer cell lines treated with erastin for 12 h. A549, 4 μM; CAL51, 20 μM; HN6, 20 μM; HT1080, 1 μM; MDA-MB-231, 2 μM; MCF7, 20 μM . D Schematic of the endocytosis assays. TFR1 in the cell surface were labelled with TFR1-specific antibodies at 4 °C followed by transferring cells to 37 °C to allow TFR1 internalization. The internalization levels of TFR1 will be established by antibody-labelled TFR1 from the cell surface evaluated by flow cytometry. This figure was created in BioRender. Lichao, L. (2025) https://BioRender.com/p1ntlvc . E Endocytosis assays of TFR1 in various cancer cell lines treated with erastin for 12 h. A549, 4 μM; CAL51, 20 μM; HN6, 20 μM; HT1080, 1 μM; MDA-MB-231, 2 μM; MCF7, 20 μM. F PKCβ was knocked out using single guide RNAs (sgRNAs) in MDA-MB-231 (left) and HT1080 (right) cells. G Total (left) and divalent (right) iron levels in the indicated MDA-MB-231 cells treated with erastin for 12 h. H , I Endocytosis assays of TFR1 in the indicated MDA-MB-231 ( H ) and HT1080 ( I ) cells treated with 2 μM or 1 μM erastin for 12 h, respectively. The cells with blue highlight were kept in 4 °C for dormancy. The cells with red highlight were transferred to 37 °C for internalization. The cells with grey highlight were labelled with non-specific antibody as isotype control. J , K Plasmids of PKCβⅠ or PKCβⅡ were transfected into PKCβ -knockout MDA-MB-231 ( J ) and HT1080 ( K ) cells, respectively. Endocytosis assays of TFR1 were performed in these cells treated with 2 μM or 1 μM erastin for 12 h, respectively. L Total (left) and divalent (right) iron levels in the indicated MDA-MB-231 cells treated with erastin for 12 h. A , F , J , K Data are representative of n = 3 biologically independent experiments. B , C , E , J , K Data are presented as means ± SD, n = 3 biologically independent experiments, unpaired two-tailed Student’s t test. G–I , L Data are presented as means ± SD, n = 3 biologically independent experiments, one-way ANOVA test.

Article Snippet: We labelled cells with TFR1-specific antibody (Proteintech, 66180-1-Ig) diluted at a ratio of 1:200 and incubated on ice for 1 h, followed by washing cells to remove unbound antibody.

Techniques: Transferring, Flow Cytometry, Control, Transfection, Knock-Out, Two Tailed Test